Cost-effectiveness of human papillomavirus vaccination in Germany

Damm, Oliver; Horn, Johannes; Mikolajczyk, Rafael T.; Kretzschmar, Mirjam E. E.; Kaufmann, Andreas M.; Deleré, Yvonne; Ultsch, Bernhard; Wichmann, Ole; Krämer, Alexander; Greiner, Wolfgang

doi:10.1186/s12962-017-0080-9

Cost Effectiveness and Resource Allocation

Table 9 Comparison with previously published models on the cost-effectiveness of HPV vaccination in Germany

From: Cost-effectiveness of human papillomavirus vaccination in Germany

Study	Type of model	Type of economic analysis	Economic outcome measure	Diseases included	Vaccination strategy	Perspective	Duration of protection	Results (€/QALY or BCR)	Funding source
Present study	Dynamic	CEA^a; CUA	ICER (€/QALY)^a	CIN, cervical cancer, and genital warts	Bivalent and quadrivalent vaccination of females and males (2 and 3 doses; 50% coverage)	Health care payer and society	20 years	13,248–34,249 (bivalent vaccination of females)^b; cost-saving to 14,711 (quadrivalent vaccination of females)^b; 77,607–130,449 (additional bivalent vaccination of males)^b; 68,118–117,240 (additional quadrivalent vaccination of males)^b	Independent
Hillemanns et al. [69]	Static	CEA^a; CUA	ICER (€/QALY)^a	CIN, cervical cancer, and genital warts	Quadrivalent vaccination of females (3 doses; 80% coverage)	Health care payer	Lifelong	10,530	Industry
Hillemanns et al. [69]	Static	CEA^a; CUA	ICER (€/QALY)^a	CIN, cervical cancer, and genital warts	Quadrivalent vaccination of females (3 doses; 80% coverage)	Health care payer	20 years	19,445	Industry
Kotsopoulos et al. [66]	Static	CBA	BCR	CIN, cervical cancer, vaginal cancer, vulvar cancer, anal cancer, and genital warts	Quadrivalent vaccination of females and males (2 doses; 55% coverage)	Society	Not reported	3.3 (vaccination of females); 0.3 (vaccination of male); 1.8 (vaccination of males and females)	Industry
Schobert et al. [67]	Dynamic	CEA^a; CUA	ICER (€/QALY)^a	CIN, cervical cancer, and genital warts	Quadrivalent vaccination of females (3 doses; 45–55% coverage)	Health care payer	Lifelong	5525	Industry
Schobert et al. [67]	Dynamic	CEA^a; CUA	ICER (€/QALY)^a	CIN, cervical cancer, and genital warts		Health care payer	20 years	About 10,000	Industry
Soergel et al. [68]	Static	CEA^a; CUA	ICER (€/QALY)^a	Neonatal morbidity and mortality due to conisation-associated prematurity	Bivalent vaccination of females (3 doses; 30–90% coverage)	Not reported	Lifelong	43,505–47,885^c	Independent

BCR benefit–cost ratio, CBA cost–benefit analysis, CEA cost-effectiveness analysis, CUA cost-utility analysis, CIN cervical intraepithelial neoplasia, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year
^aCEA results are not presented in the table
^bDepending on the perspective and the number of doses
^cDepending on the utility values

Back to article page

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com